SAB Biotherapeutics FY 2023 Operating and Financial Results
Friday, 29 March 2024, 11:17
SAB Biotherapeutics FY 2023 Operating and Financial Results
In the latest fiscal year report, SAB Biotherapeutics announced a GAAP EPS of -$7.64, missing expectations by $3.43. However, the company managed to beat revenue estimates, recording $2.24M in revenue for the year.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.